

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2018 September 28; 24(36): 4093-4216



**EDITORIAL**

- 4093** Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease  
*Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C*

**REVIEW**

- 4104** Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease  
*Torres JL, Novo-Veleiro I, Manzanedo L, Alvela-Suárez L, Macías R, Laso FJ, Marcos M*
- 4119** Calcium-sensing receptor in colorectal inflammation and cancer: Current insights and future perspectives  
*Iamartino L, Elajna T, Kallay E, Schepelmann M*
- 4132** Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis  
*Yang F, Chen GX*

**MINIREVIEWS**

- 4152** Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?  
*Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassinetti GL, Scartozzi M, Casadei Gardini A*

**ORIGINAL ARTICLE****Basic Study**

- 4164** Differential expression of mucin 1 and mucin 2 in colorectal cancer  
*Kasprzak A, Siodla E, Andrzejewska M, Szmaja J, Seraszek-Jaros A, Cofta S, Szaflarski W*
- 4178** Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt/ $\beta$ -catenin signalling pathway  
*Huang GR, Wei SJ, Huang YQ, Xing W, Wang LY, Liang LL*

**Retrospective Study**

- 4186** Frequency, types and treatment of anemia in Turkish patients with inflammatory bowel disease  
*Bengi G, Keyvan H, Durmaz SB, Akpınar H*

**Prospective Study**

- 4197** Low-dose spectral insufflation computed tomography protocol preoperatively optimized for T stage esophageal cancer - preliminary research experience  
*Zhou Y, Liu D, Hou P, Zha KJ, Wang F, Zhou K, He W, Gao JB*

**CASE REPORT**

- 4208** Novel methionyl-tRNA synthetase gene variants/phenotypes in interstitial lung and liver disease: A case report and review of literature  
*Abuduxikuer K, Feng JY, Lu Y, Xie XB, Chen L, Wang JS*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Matthias Ocker, MD, Professor, Department of Oncology Translational Medicine, Bayer AG, Berlin 13353, Germany

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7<sup>th</sup>, 14<sup>th</sup>, 21<sup>st</sup>, and 28<sup>th</sup> each month. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

*World Journal of Gastroenterology* (*WJG*) is now indexed in Current Contents<sup>®</sup>/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch<sup>®</sup>), Journal Citation Reports<sup>®</sup>, Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2018 edition of Journal Citation Reports<sup>®</sup> cites the 2017 impact factor for *WJG* as 3.300 (5-year impact factor: 3.387), ranking *WJG* as 35<sup>th</sup> among 80 journals in gastroenterology and hepatology (quartile in category Q2).

**EDITORS FOR THIS ISSUE**

Responsible Assistant Editor: *Xiang Li*  
Responsible Electronic Editor: *Yan Huang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Rao-Yu Ma*  
Proofing Editorial Office Director: *Ze-Mao Gong*

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print)  
ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

**Andrzej S Tarnawski, MD, PhD, DSc (Med),  
Professor of Medicine, Chief Gastroenterology, VA  
Long Beach Health Care System, University of California,  
Irvine, CA, 5901 E. Seventh Str., Long Beach,  
CA 90822, United States**

**EDITORIAL BOARD MEMBERS**

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**

Ze-Mao Gong, Director  
*World Journal of Gastroenterology*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**

Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLICATION DATE**

September 28, 2018

**COPYRIGHT**

© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**

<http://www.f6publishing.com>

## Basic Study

# Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt/ $\beta$ -catenin signalling pathway

Gan-Rong Huang, Si-Jun Wei, Yan-Qiang Huang, Wei Xing, Lu-Yao Wang, Ling-Ling Liang

Gan-Rong Huang, Yan-Qiang Huang, Wei Xing, Lu-Yao Wang, Ling-Ling Liang, Youjiang Medical University for Nationalities, School of Basic Medical Sciences, Baise 533000, Guangxi Zhuang Autonomous Region, China

Si-Jun Wei, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region, China

ORCID number: Gan-Rong Huang (0000-0001-5580-8689); Si-Jun Wei (0000-0001-6948-2747); Yan-Qiang Huang (0000-0002-2121-8258); Wei Xing (0000-0001-5640-1151); Lu-Yao Wang (0000-0001-5545-0170); Ling-Ling Liang (0000-0002-1498-2370).

**Author contributions:** Huang GR and Wei SJ contributed equally to this work; Huang YQ, Wang LY and Liang LL performed the majority of the experiments; Xing W performed the experimental design, writing and analysis.

**Supported by** Key Laboratory Cultivation Base of Universities in Guangxi (Guangxi Education Research), No. [2014] 6.

**Institutional animal care and use committee statement:** This study was reviewed and approved by the Youjiang Medical University for Nationalities.

**Conflict-of-interest statement:** All authors have no conflict of interest.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The manuscript has been revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

**Correspondence to:** Wei Xing, MD, Professor, Youjiang Medical University for Nationalities, School of Basic Medical Sciences, 98 Urban-Rural Road, Baise 533000, Guangxi Zhuang Autonomous Region, China. 116895009@qq.com  
Telephone: 18907767511

Received: June 5, 2018

Peer-review started: June 5, 2018

First decision: June 21, 2018

Revised: July 30, 2018

Accepted: August 1, 2018

Article in press: August 1, 2018

Published online: September 28, 2018

## Abstract

### AIM

To reveal the protective mechanism of the combined use of vitamin D and puerarin in the progression of hepatic fibrosis induced by carbon tetrachloride (CCl<sub>4</sub>).

### METHODS

Eight-week-old male Wistar rats were randomly divided into a normal control group (C group), a CCl<sub>4</sub> group (CCl<sub>4</sub> group), a vitamin D group (V group), a puerarin group (P group), and a combined group of vitamin D and puerarin (V + P group), each of which contained ten rats. In this way, we built a rat model of CCl<sub>4</sub>-induced hepatic fibrosis with intervention by vitamin D, puerarin, or a combination of the two. After eight weeks, the mice were sacrificed to collect serum and liver specimens. Blood was collected to detect the hyaluronic acid (HA). We also measured hydroxyproline (Hyp) and prepared paraffin sections of liver. After Sirius red staining, the liver specimens were observed under a microscope. RT-PCR and western blot analysis were adopted to detect the mRNA and the protein



levels of Collagen I, Collagen III, Wnt1, and  $\beta$ -catenin in the liver tissues, respectively.

## RESULTS

Hepatic fibrosis was observed in the CCl<sub>4</sub> group. In comparison, hepatic fibrosis was attenuated in the V, P, and V + P groups: the HA level in blood and the Hyp level in liver were reduced, and the mRNA levels of Collagen I, Collagen III, Wnt, and  $\beta$ -catenin in liver were also decreased, as well as the protein levels of Wnt1 and  $\beta$ -catenin. Among these groups, the V + P group demonstrated the greatest amelioration of hepatic fibrosis.

## CONCLUSION

The combined application of vitamin D and puerarin is capable of alleviating CCl<sub>4</sub>-induced hepatic fibrosis of rats. As to the mechanism, it is probably because the combined use is able to silence the Wnt1/ $\beta$ -catenin pathway, suppress the activation of hepatic stellate cells, and reduce the secretion of collagen fibers, therefore improving the anti-hepatic fibrosis effect.

**Key words:** Carbon tetrachloride; Hepatic fibrosis; Vitamin D; Puerarin; Wnt/ $\beta$ -catenin

© **The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The proliferation of hepatic stellate cells (HSCs) is associated with hepatic fibrosis. The activated HSCs, as well as Wnt1 and  $\beta$ -catenin, have become important targets in anti-hepatic fibrosis therapy. This research investigated the protective effect of the combined use of vitamin D and puerarin against CCl<sub>4</sub>-induced hepatic fibrosis in rats. The protective effect of the combined use of vitamin D and puerarin in the progression of hepatic fibrosis is closely associated with the function of silencing the Wnt1/ $\beta$ -catenin pathway, suppressing the activation of HSCs, and decreasing the secretion of collagen fibers, which provided a useful reference for those in clinical practice.

Huang GR, Wei SJ, Huang YQ, Xing W, Wang LY, Liang LL. Mechanism of combined use of vitamin D and puerarin in anti-hepatic fibrosis by regulating the Wnt/ $\beta$ -catenin signalling pathway. *World J Gastroenterol* 2018; 24(36): 4178-4185 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v24/i36/4178.htm> DOI: <http://dx.doi.org/10.3748/wjg.v24.i36.4178>

## INTRODUCTION

Hepatic fibrosis is the change of pathological structures due to all kinds of chronic liver diseases. Essentially, it occurs because extracellular matrix (ECM) synthesized by hepatic stellate cells (HSCs) under the actions of various pathogenic factors substantially increases,

exceeding the degradation ability of the liver itself. The long-term accumulation of ECM will lead to hepatic fibrosis and thus cause liver cirrhosis<sup>[1,2]</sup>. In recent years, it has been proven that the  $\beta$ -catenin protein plays a critical role in the occurrence and development of hepatic fibrosis<sup>[3,4]</sup>. Previous studies revealed that the more serious the hepatic fibrosis, the higher the expression of  $\beta$ -catenin in liver tissues compared with normal liver tissues, and silencing  $\beta$ -catenin is able to suppress the secretion of collagen and the proliferation of HSCs and mediate cell apoptosis.  $\beta$ -catenin participates in many signalling pathways, among which the Wnt/ $\beta$ -catenin pathway is the most common along which  $\beta$ -catenin plays its role. Apart from this,  $\beta$ -catenin also participates in alternative pathways including E-cadherin, NF- $\kappa$ B, and TGF- $\beta$ <sup>[5-7]</sup>. Therefore,  $\beta$ -catenin is key to the intersection of multiple signalling pathways. Existing experiments revealed that HSC-T6 cell membranes and cytoplasm with activated phenotypes show  $\beta$ -catenin expression, and  $\beta$ -catenin expression is also observed in nuclei. This indicates that the Wnt/ $\beta$ -catenin signalling pathway is activated in activated HSCs. The expression of  $\alpha$ -SMA in HSC-T6 cells was down-regulated by blocking the transduction of the Wnt/ $\beta$ -catenin signalling pathway, and the expression of types I and III collagen (Collagen I and Collagen III) was also significantly down-regulated. The analysis based on the String database finds that DVL1, DVL2, and DVL3 play their functions in signal transduction pathways mediated by multiple Wnt genes. They are regulatory factors for the Wnt signalling pathway and ER-to-Golgi transport and participate in the ER-to-Golgi transport, thus KLHL12 plays a critical role in the export of collagen, as shown in Figure 1. This implies that the Wnt/ $\beta$ -catenin signalling pathway is closely associated with the activation of HSCs.

Carbon tetrachloride (CCl<sub>4</sub>) is one of the classical poisons used in establishing hepatic fibrosis models and is therefore widely used in fundamental research<sup>[8]</sup>. Previous research has proven *in vivo* that vitamin D is able to alleviate hepatic fibrosis, and *in vitro* experiments confirmed that vitamin D can reduce the secretion of collagen fibers of HSCs<sup>[9,10]</sup>. There are also evidences from existing research that puerarin is capable of attenuating hepatic fibrosis, which is probably associated with the inhibition of the activation of HSCs by blocking the TNF- $\alpha$  signalling pathway<sup>[11,12]</sup>. A preliminary study by the present research team has confirmed that the combined use of vitamin D and puerarin is able to enhance the anti-hepatic fibrosis effect; however, the related mechanism has not been revealed. Therefore, the current research investigated the effects of vitamin D combined with puerarin on the expression of key factors, including Wnt1,  $\beta$ -catenin, Collagen I, and Collagen III, in the Wnt/ $\beta$ -catenin signalling pathway based on the aforementioned preliminary study. By doing so, we attempted to further clarify the mechanism of the combined use of vitamin D

Table 1 Designations and sequences of primers

Designation (mice)	Sequence (5'-3')
GAPDH	F: GGCATCCTGACCCCTCAAGTA R: GGGGTGTGAACCTCTCAAA
Collagen I	F: GGACACTACTGGATCGACCTAAC R: CTCACCTGTCTCCATGTTGCA
Collagen III	F: CTACCTTGCTCAGTCCTATGAGTCTAGA R: TCCCGAGTCGCAGACACATAT
Wnt1	F: GAAACCGCCGCTGGAACCT R: CCGTCCTCGTATATGTGAAG
β-catenin	F: ACC TCC CAAGTC CTG TAT R: CCT GGT CCT CGT CAT TTA




Figure 1 Interaction between WNT-related genes and collagen-related genes.

and puerarin in anti-hepatic fibrosis.

## MATERIALS AND METHODS

### Experimental materials

Fifty clean-grade healthy male Wistar rats (with a body mass of about 200 g) of similar age were provided by the Animal Center of Youjiang Medical College for Nationalities. Analytically pure CCl<sub>4</sub> was purchased from Sinopharm Chemical Reagent Co., Ltd, and vitamin D and puerarin were purchased from Sigma. In addition, corn oil, Sirius red staining solution, and real-time fluorescence quantitative PCR kits were purchased from Wako Pure Chemical Industries, Ltd, Beijing Leagene Biotech Co., Ltd, and Roche (Switzerland), respectively. Wnt1 and β-catenin antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, United States). Table 1 shows the designations and sequences of primers.

### Experimental methods

Fifty Wistar rats were randomly divided into five groups. Rats in the CCl<sub>4</sub> group were administered 3 mL/kg of corn oil solution containing 45% CCl<sub>4</sub> through intraperitoneal injection twice a week. The normal control group (C group) was administered the same dose of normal saline through intraperitoneal injection twice a week. The V, P, and V + P groups were the drug intervention

groups. On the basis of the models established using corn oil solution containing CCl<sub>4</sub>, mice in the three groups received 2 μg/kg of vitamin D, 0.4 g/kg of puerarin, and a combination of D vitamin (2 μg/kg) and puerarin (0.4 g/kg) through intragastric administration twice a week. The mice were subjected to fasting for one hour before each administration of treatment. The C group received the same quantity of normal saline through intragastric administration. After eight weeks, the mice were fasted overnight the day before the end of the experiments and sacrificed the next day. Whole blood was collected and stood for 20 min at room temperature. Then, the blood was centrifuged at 5000 rpm for 15 min. Thereafter, the supernatant and then the serum were obtained, followed by the detection of hyaluronic acid (HA) in blood using the aforementioned kit. After collecting the liver of the rats, the kit was used to detect hydroxyproline (Hyp) in the liver. Part of the liver was fixed in a paraformaldehyde solution, and paraffin sections were prepared. After Sirius red staining, liver tissue slices were placed under the microscope to observe their pathological changes and degree of fibrosis. Moreover, real-time fluorescence quantitative PCR was applied to detect the mRNA levels of Collagen I, Collagen III, Wnt1, and β-catenin, and a western blot assay was used to measure the protein levels of Wnt1 and β-catenin.

### Statistical analysis

The experiments were repeated three times for each group. SPSS 17.0 statistical software was used for subsequent analysis. The analytical results were expressed using mean ± SD, and a *t*-test was used when comparing paired groups. The difference was deemed statistically significant when *P* < 0.05.

## RESULTS

### Determination of biochemical indices of blood and liver

HA is a type of proteoglycan distributed around hepatic cells, and its content significantly increases in blood when hepatic fibrosis occurs<sup>[13]</sup>. Hyp in liver is an important part of the collagen fibers in liver, and the amount thereof also increases when hepatic fibrosis occurs<sup>[14]</sup>. Therefore, these two factors are important diagnostic indices of hepatic fibrosis. As shown in Table 2, the HA and Hyp of the CCl<sub>4</sub> group were significantly higher than those of the C group, which indicated, to some extent, that the hepatic fibrosis model had been successfully established. The HA and Hyp levels of the V, P, and V + P groups were much lower than those of the CCl<sub>4</sub> group. Among these groups, the V + P group showed the most significant reduction in HA and Hyp levels.

### Observation of the pathological sections of liver tissues

The Sirius-red-stained sections of each group were observed under the microscope. As illustrated in Figure 2A-F, mice in the CCl<sub>4</sub> group and the medication groups

**Table 2** Biochemical indices of blood and liver

Groups	HA (μg/L)	Hyp (μg/g)
C	61 ± 20.6 <sup>bcd</sup>	195.6 ± 10.5 <sup>bcd</sup>
CCl <sub>4</sub>	157.3 ± 44.3 <sup>acde</sup>	503 ± 31.7 <sup>acde</sup>
V	70.2 ± 12.9 <sup>b</sup>	375.2 ± 26.9 <sup>ab</sup>
P	79.5 ± 11.6 <sup>b</sup>	361.3 ± 24.1 <sup>ab</sup>
V + P	65 ± 12.1 <sup>b</sup>	353.7 ± 21.6 <sup>ab</sup>

In the comparison of the mean ± standard deviation (SD) of various groups, differences are statistically significant when  $P < 0.05$ , with  $n = 10$ . In addition, a, b, c, d, and e represent statistical differences vs C, CCl<sub>4</sub>, V, P, and V + P groups, respectively. C: Control; V: Vitamin; P: Puerarin.

showed larger areas of fibrosis in their liver tissues than in the C group. In addition, the areas of fibrosis of liver tissues in rats in each of the medicated groups were smaller than that of the CCl<sub>4</sub> group ( $P < 0.05$ ). Among the three groups, the V + P group presented the smallest area of fibrosis.

#### **mRNA levels of collagen I, collagen III, Wnt1, and β-catenin**

RT-PCR detection was conducted to test the mRNA levels of Collagen I, Collagen III, Wnt1, and β-catenin of the rats in each group. It can be seen from Table 3 that the mRNA levels of Collagen I, Collagen III, Wnt1, and β-catenin of liver tissues of rats in the CCl<sub>4</sub> group and the medicated groups are all higher than those of the C group. The mRNA levels of these indices of rats in the three medicated groups were all lower than those of the CCl<sub>4</sub> group ( $P < 0.05$ ). Among the medicated groups, the V + P group showed the lowest mRNA levels.

#### **Protein levels of Wnt1 and β-catenin of liver**

As the Wnt/β-catenin signalling pathway plays a significant role in the progression of hepatic fibrosis, a western blot assay was applied to detect the protein levels of Wnt1 and β-catenin in the liver. Figure 3 shows that the protein levels of Wnt1 and β-catenin in the liver tissues of rats in the CCl<sub>4</sub> group and the medicated groups were higher than the C group. The medicated groups showed lower protein levels than the CCl<sub>4</sub> group ( $P < 0.05$ ), among which the V + P group exhibited the lowest protein levels ( $P < 0.01$ ).

## **DISCUSSION**

Hepatic fibrosis is the inevitable pathological change during the development of chronic liver diseases. If it is not blocked, its further development would cause liver cirrhosis and even liver cancer. Hepatic fibrosis can be induced by many pathogenic factors, including viruses, parasites, alcohol, and some poisons such as CCl<sub>4</sub>. It is essentially a disturbance of the balance between the production and degradation of ECM outside hepatocytes. The ECM accumulates in the liver and its main component is collagen fibers<sup>[15,16]</sup>. HSCs, as the principal participants in the production and degradation

of ECM, when activated, are the key link necessary for the occurrence of hepatic fibrosis. Existing in the Disse space, HSCs mainly play their roles in metabolizing and storing vitamin A in normal conditions. They can synthesize and secrete small amounts of ECM and produce collagenase. When hepatic fibrosis occurs, HSCs in their resting state are activated. Active oxygen, lipid peroxide, and molecules secreted by nearby cells, such as activated Kupffer cells, and liver sinusoidal endothelial cells, as well as damaged hepatic cells, all can facilitate the activation of resting HSCs. After activation, HSCs have different morphologies, and the changes include the secretion of alpha smooth muscle actin (α-SMA), loss of vitamin A stored in cells, and increase in the rough endoplasmic reticulum. The activation of HSCs is also accompanied by a series of changes in genetic expression, including the appearance of receptors that can respond to paracrine stimulation on the cytomembrane of activated HSCs and a series of signalling cascade reactions in cells. The presence of the signalling cascade reactions in cells is beneficial to maintaining the phenotype of activated cells and controlling the occurrence of fibrosis, the proliferation of HSCs, and the increases in the transcription and translation of Collagen I and Collagen III<sup>[17-19]</sup>.


The canonical Wnt signal transduction pathway is also known as the Wnt/β-catenin signal transduction pathway. It is the pathway that has been the subject of most of the research to date. As a highly conserved signalling pathway activated during the evolution of some species, it is a basic pathway that is able to regulate cell proliferation and cell polarity, control cell fate, and maintain homeostasis in the embryo, and influence tissue development. Therefore, the pathway plays significant roles in various physiological processes including early development of animal embryos, organogenesis, and tissue regeneration, as shown in Figure 4<sup>[20]</sup>. When Wnt is deficient, β-catenin in the cytoplasm is generally degraded via Axin complexes; in addition, glycogen and casein kinase 1 (CK1) synthesize glycogen synthase kinase 3 (GSK3), which sequentially phosphorylates the amino terminus of β-catenin. As a result, β-catenin is recognized by β-Trcp and the sub-unit of E3 ubiquitin ligases and is then degraded by the ubiquitination pathway. The continuous removal of β-catenin inhibits the nuclear import of β-catenin and the combination of the protein family of T cell factor/lymphoid enhancer factor (TCF/LEF) with DNA, thus suppressing the transcription of Wnt target genes<sup>[21,22]</sup>. When Wnt ligands are bound with transmembrane Frizzled (Fz) receptors and their co-receptor-low-density lipoprotein receptor related protein 6 (LRP6) or similar LRP5, the Wnt/β-catenin signalling pathway and dishevelled Dsh/Dvl proteins in cells are activated. Consequently, the GSK-3β activity is suppressed, Axin falls off, and the formation of biodegradable composite film (mainly composed of Axin, APC, and GSK-3β) of β-catenin is inhibited. Therefore, β-catenin



**Table 3** The mRNA levels of collagen I, collagen III, Wnt1, and  $\beta$ -catenin of liver

Groups	Collagen I	Collagen III	Wnt1	$\beta$ -catenin
C	1.17 $\pm$ 0.16 <sup>bcd</sup>	0.62 $\pm$ 0.15 <sup>bcd</sup>	0.56 $\pm$ 0.13 <sup>bcd</sup>	0.48 $\pm$ 0.21 <sup>bcd</sup>
CCl <sub>4</sub>	4.73 $\pm$ 0.76 <sup>acde</sup>	2.47 $\pm$ 1.12 <sup>acde</sup>	1.77 $\pm$ 0.32 <sup>acde</sup>	2.16 $\pm$ 0.42 <sup>acde</sup>
V	1.97 $\pm$ 0.31 <sup>b</sup>	1.29 $\pm$ 0.19 <sup>ab</sup>	1.06 $\pm$ 0.35 <sup>ab</sup>	1.25 $\pm$ 0.33 <sup>ab</sup>
P	1.75 $\pm$ 0.46 <sup>b</sup>	1.35 $\pm$ 0.17 <sup>ab</sup>	0.83 $\pm$ 0.19 <sup>ab</sup>	0.71 $\pm$ 0.46 <sup>ab</sup>
V + P	1.53 $\pm$ 0.12 <sup>abcd</sup>	1.03 $\pm$ 0.08 <sup>abcd</sup>	0.61 $\pm$ 0.24 <sup>abcd</sup>	0.59 $\pm$ 0.14 <sup>abcd</sup>

Differences are considered to exhibit statistical significance when  $P < 0.05$  ( $n = 10$ ) in the comparison of the mean  $\pm$  standard deviation (SD) between various groups. a, b, c, d, and e indicate that there are statistical differences *vs* C, CCl<sub>4</sub>, V, P, and V + P groups, respectively. C: Control; V: Vitamin; P: Puerarin.




**Figure 2** Sirius red staining. A: Control (C) group; B: CCl<sub>4</sub> group; C: Vitamin D (V) group; D: Puerarin (P) group; E: V + P group (200  $\times$  magnification); F: Statistical graph of positive Sirius-red-stained areas (in the comparison of the mean  $\pm$  SD of various groups, differences are statistically significant when  $P < 0.05$ ,  $n = 10$ . a, b, c, d, and e represent statistical differences *vs* C, CCl<sub>4</sub>, V, P, and V + P groups, respectively).

will aggregate, not be recognized, and degraded *via* the ubiquitination pathway<sup>[23,24]</sup>. As  $\beta$ -catenin accumulates to a certain level, it dissociates. Under these conditions,  $\beta$ -catenin is likely to undergo nuclear translocation, thus combining with the transcription factor TCF/LEF, forming transcriptional activation complex, and finally upregulating or downregulating the expressions of some downstream genes. At present, the known target

downstream genes include D1 (cyclin D1), c-myc, MMP7, survivin, CD44, and growth factor, and new target genes are constantly being discovered<sup>[25,26]</sup>. In the Wnt/ $\beta$ -catenin pathway, Wnt1 is the key gene participating in the aggregation and disappearance of  $\beta$ -catenin and is closely related to the occurrence and development of hepatic fibrosis and tumors.

The Wnt/ $\beta$ -catenin pathway and the activation and





**Figure 3** The protein levels of Wnt1 and  $\beta$ -catenin of liver tissues in rats in the CCl<sub>4</sub> group and the medicated groups were higher than the Control (C) group. A: Detection of protein levels of Wnt1, and  $\beta$ -catenin using western blot assay; B: Grey analysis of Wnt1; C: Grey analysis of  $\beta$ -catenin [in the comparison of mean  $\pm$  standard deviation (SD) of various groups, differences are statistically significant when  $P < 0.05$ ,  $n = 10$ . In addition, a, b, c, d, and e represent statistical differences vs C, CCl<sub>4</sub>, V, P, and V + P groups, respectively]. C: Control; V: Vitamin; P: Puerarin.


proliferation of HSCs are therefore associated with hepatic fibrosis. The Wnt/ $\beta$ -catenin pathway, dominated as it is by Wnt and  $\beta$ -catenin, plays a significant role in regulating the activation of HSCs and the secretion of Collagen I and III. Although the mechanism *via* which the Wnt/ $\beta$ -catenin signalling pathway takes part in hepatic fibrosis by activating HSCs is not completely understood, activated HSCs, as well as Wnt1 and  $\beta$ -catenin, have become important targets in anti-hepatic fibrosis therapy.

Most of the vitamin D in the body is produced by the liver, which is also one of the target organs of vitamin D. Previous studies have revealed that vitamin D is capable of ameliorating CCl<sub>4</sub>-induced hepatic fibrosis in mice. *In vitro* experiments have shown that this is probably because it reduces the activation of HSCs and the secretion of collagen fibers. Puerarin, as a type of flavonoid drug that is widely applied in clinical practice, is also able to alleviate CCl<sub>4</sub>-induced hepatic fibrosis (according to the evidence of existing research): however, there is no report on the issue as to whether the Wnt/ $\beta$ -catenin signalling pathway can be significantly suppressed after the combined use of vitamin D and puerarin. Whether using vitamin D or puerarin alone, their protective effects on the liver during the progression of hepatic fibrosis have been found to be closely associated with their functions of suppressing HSCs. Our preliminary research revealed that the combined use of the two drugs is able to impart

greater protective function, so we speculated that the mechanism of the combined use is probably related to HSCs, Wnt, and  $\beta$ -catenin.

The research demonstrated that CCl<sub>4</sub> greatly increased the HA level in blood and Hyp level in rat liver. By observing the Sirius-red-stained specimens under a microscope, it was found that CCl<sub>4</sub> caused the deposition of collagen fibers in the liver of the rats. All these results indicated that the rat model of hepatic fibrosis was successfully established. Vitamin D and puerarin can both reduce the HA level in blood and Hyp level in liver of the rats, thus greatly decreasing the amount of collagen fibers in the liver. The combined use of vitamin D and puerarin most significantly reduced various damage indices and alleviated the deposition of collagen fibers, which proved that the two drugs have synergistic effects. Meanwhile, we detected the mRNA and protein levels of Collagen I, Collagen III, Wnt1, and  $\beta$ -catenin molecules in the liver of the rats. The results indicated that both vitamin D and puerarin are capable of decreasing the mRNA and protein levels of these molecules. Likewise, the most significant reduction effect was also observed in the V + P group. This suggested that the protective effect of the combined use of vitamin D and puerarin in the progression of hepatic fibrosis is closely associated with the functions of silencing the Wnt1/ $\beta$ -catenin pathway, suppressing the activation of HSCs, and decreasing the secretion of collagen fibers.

The research investigated the protective effect of the



**Figure 4 Overview of WNT/β-catenin signalling.** Without WNT signalling ("WNT OFF"), the destruction complex phosphorylates cytosolic β-catenin, and phosphorylated β-catenin is recognized and degraded by the proteasomes. With active WNT signalling ("WNT ON"), the function of the "destruction complex" is inhibited to phosphorylate cytosolic β-catenin. Then unphosphorylated β-catenin accumulates in the cytosol, translocates into the nucleus, and activates WNT target gene expression, such as the targets of the T-cell factor and lymphoid enhancer factor-1 (TCF/LEF1) family of transcription factors.

combined use of vitamin D and puerarin against CCl<sub>4</sub>-induced hepatic fibrosis in rats. The results revealed that the combined use of the two drugs exhibited a superior anti-hepatic fibrosis effect compared to that of each of the agents used as a single medication. It was preliminarily found that the protective mechanism of the combined use was related to the Wnt/β-catenin pathway, which provided a useful reference for those in clinical practice. However, the regulatory mechanism is complex and involves multiple factors and pathways. Other mechanisms of action warrant further investigation.

## ARTICLE HIGHLIGHTS

### Research background

Hepatic fibrosis is seriously endangering the safety of life. At present, there is no ideal way to treat hepatic fibrosis. The combination of vitamin D and puerarin can improve the effects of anti-hepatic fibrosis, but the mechanism is not clear. Therefore, the aim of this study is to explore the mechanism of the combined use of vitamin D and puerarin in the treatment of hepatic fibrosis, so as to improve the theoretical basis for the treatment of hepatic fibrosis.

### Research motivation

The combination of vitamin D and puerarin can improve the effect of anti-hepatic fibrosis, but its mechanism is not clear. The Wnt/β-catenin pathway is closely related to liver fibrosis. In this study, we found that vitamin D and puerarin are closely related to the regulation of Wnt/β-catenin pathway in hepatic fibrosis, which provided a useful reference for those in clinical practice.

### Research objectives

The research aimed to reveal the protective mechanism of the combined use of vitamin D and puerarin in the progression of hepatic fibrosis induced by carbon

tetrachloride (CCl<sub>4</sub>).

### Research methods

In this study, a Wistar rat model of hepatic fibrosis was constructed by CCl<sub>4</sub>. Vitamin D combined with puerarin was used in the treatment of hepatic fibrosis rats, and the liver pathology and the genes related to the Wnt/β-catenin pathway were detected. The protective mechanism of the combined use of vitamin D and puerarin in the progression of hepatic fibrosis was explored at the molecular level.

### Research results

The research demonstrated that CCl<sub>4</sub> greatly increased the HA level in blood and Hyp level in the rat liver. CCl<sub>4</sub> caused the deposition of collagen fibers in the liver of the rats. Vitamin D and puerarin can both reduce the HA level in blood and Hyp level in liver of the rats, thus greatly decreasing the amount of collagen fibers in the liver. The combined use of vitamin D and puerarin most significantly reduced the various damage indices, and alleviated the deposition of collagen fibers, which proved that the two drugs had synergistic effects.

### Research conclusions

The combined application of vitamin D and puerarin is capable of alleviating the CCl<sub>4</sub>-induced hepatic fibrosis of rats.

### Research perspectives

We have learned to induce an animal model of hepatic fibrosis and study the drug effects by the animal model, but also because we were not skilled enough in the experimental technique and spent more time doing repetitive work. The future research direction is to explore the prevention and treatment measures of hepatic fibrosis. The drug targets will be studied by transcriptome, proteomics and other methods.

## REFERENCES

- 1 Ding BS, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, Penfold ME,

- Shido K, Rabbany SY, Rafii S. Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. *Nature* 2014; **505**: 97-102 [PMID: 24256728 DOI: 10.1038/nature12681]
- 2 **Friedman SL.** Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem* 2000; **275**: 2247-2250 [PMID: 10644669 DOI: 10.1074/jbc.275.4.2247]
- 3 **Ge WS,** Wang YJ, Wu JX, Fan JG, Chen YW, Zhu L.  $\beta$ -catenin is overexpressed in hepatic fibrosis and blockage of Wnt/ $\beta$ -catenin signaling inhibits hepatic stellate cell activation. *Mol Med Rep* 2014; **9**: 2145-2151 [PMID: 24691643 DOI: 10.3892/mmr.2014.2099]
- 4 **Li W,** Zhu C, Li Y, Wu Q, Gao R. Mest attenuates CCl<sub>4</sub>-induced liver fibrosis in rats by inhibiting the Wnt/ $\beta$ -catenin signaling pathway. *Gut Liver* 2014; **8**: 282-291 [PMID: 24827625 DOI: 10.5009/gnl.2014.8.3.282]
- 5 **Barrott JJ,** Cash GM, Smith AP, Barrow JR, Murtaugh LC. Deletion of mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia/Goltz syndrome. *Proc Natl Acad Sci USA* 2011; **108**: 12752-12757 [PMID: 21768372 DOI: 10.1073/pnas.1006437108]
- 6 **Qian J,** Niu M, Zhai X, Zhou Q, Zhou Y.  $\beta$ -catenin pathway is required for TGF- $\beta$ 1 inhibition of PPAR $\gamma$  expression in cultured hepatic stellate cells. *Pharmacol Res* 2012; **66**: 219-225 [PMID: 22706027 DOI: 10.1016/j.phrs.2012.06.003]
- 7 **Nejak-Bowen K,** Kikuchi A, Monga SP. Beta-catenin-NF- $\kappa$ B interactions in murine hepatocytes: a complex to die for. *Hepatology* 2013; **57**: 763-774 [PMID: 22941935 DOI: 10.1002/hep.26042]
- 8 **Ma ZG,** Lv XD, Zhan LL, Chen L, Zou QY, Xiang JQ, Qin JL, Zhang WW, Zeng ZJ, Jin H, Jiang HX, Lv XP. Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymal stem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway. *World J Gastroenterol* 2016; **22**: 2092-2103 [PMID: 26877613 DOI: 10.3748/wjg.v22.i6.2092]
- 9 **Abramovitch S,** Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, Reif S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. *Gut* 2011; **60**: 1728-1737 [PMID: 21816960 DOI: 10.1136/gut.2010.234666]
- 10 **Ding N,** Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, Leblanc M, Coulter S, He M, Scott C, Lau SL, Atkins AR, Barish GD, Gunton JE, Liddle C, Downes M, Evans RM. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. *Cell* 2013; **153**: 601-613 [PMID: 23622244 DOI: 10.1016/j.cell.2013.03.028]
- 11 **Li R,** Xu L, Liang T, Li Y, Zhang S, Duan X. Puerarin mediates hepatoprotection against CCl<sub>4</sub>-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function. *Food Chem Toxicol* 2013; **52**: 69-75 [PMID: 23146695 DOI: 10.1016/j.fct.2012.10.059]
- 12 **Kaji K,** Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshii J, Yanase K, Kitade M, Namisaki T, Fukui H. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. *J Gastroenterol* 2014; **49**: 481-491 [PMID: 23475323 DOI: 10.1007/s00535-013-0783-4]
- 13 **Lei X,** Wang YL, Tu-er-xun AL, Zhang H, Zhang RL, Yang Y, Wu G, Cheng W. Correlation between radiation-induced hepatic fibrosis and serum levels of hyaluronic acid, type IV collagen and laminin in rats. *Zhonghua Quanke Yixue* 2015; **13**: 18-20
- 14 **Wang ZL,** Liu ZJ, Song T, Sun XH, Luo WM, Liu S. Effects of FuzhengHuoxue recipes on liver fibrosis associated serum indicators and hepatic hydroxyproline in liver fibrosis rats. *Zhongyao Xinyao Yu Linchuang Yaoli* 2010; **21**: 611-613
- 15 **Lu J,** Chen B, Li S, Sun Q. Trypsin inhibitor APC 366 prevents hepatic fibrosis by inhibiting collagen synthesis induced by trypsin/protease-activated receptor 2 interactions in hepatic stellate cells. *Int Immunopharmacol* 2014; **20**: 352-357 [PMID: 24735816 DOI: 10.1016/j.intimp.2014.04.001]
- 16 **Wang Y,** Zhao Z, Yan Y, Qiang X, Zhou C, Li R, Chen H, Zhang Y. Demethylenberberine Protects against Hepatic Fibrosis in Mice by Modulating NF- $\kappa$ B Signaling. *Int J Mol Sci* 2016; **17**: [PMID: 27376272 DOI: 10.3390/ijms17071036]
- 17 **Schuppan D,** Kim YO. Evolving therapies for liver fibrosis. *J Clin Invest* 2013; **123**: 1887-1901 [PMID: 23635787 DOI: 10.1172/jci66028]
- 18 **Friedman SL.** Hepatic fibrosis -- overview. *Toxicology* 2008; **254**: 120-129 [PMID: 18662740]
- 19 **Atzori L,** Poli G, Perra A. Hepatic stellate cell: a star cell in the liver. *Int J Biochem Cell Biol* 2009; **41**: 1639-1642 [PMID: 19433304 DOI: 10.1016/j.biocel.2009.03.001]
- 20 **Ota C,** Baarsma HA, Wagner DE, Hilgendorff A, Königshoff M. Linking bronchopulmonary dysplasia to adult chronic lung diseases: role of WNT signaling. *Mol Cell Pediatr* 2016; **3**: 34 [PMID: 27718180 DOI: 10.1186/s40348-016-0062-6]
- 21 **Qi B,** Wang Y, Chen ZJ, Li XN, Qi Y, Yang Y, Cui GH, Guo HZ, Li WH, Zhao S. Down-regulation of miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell proliferation by activating the Wnt signaling pathway. *World J Gastroenterol* 2017; **23**: 7965-7977 [PMID: 29259372 DOI: 10.3748/wjg.v23.i45.7965]
- 22 **Wang D,** Lu G, Shao Y, Xu D. MiR-182 promotes prostate cancer progression through activating Wnt/ $\beta$ -catenin signal pathway. *Biomed Pharmacother* 2018; **99**: 334-339 [PMID: 29353209 DOI: 10.1016/j.biopha.2018.01.082]
- 23 **Wang C,** Zhu H, Sun Z, Xiang Z, Ge Y, Ni C, Luo Z, Qian W, Han X. Inhibition of Wnt/ $\beta$ -catenin signaling promotes epithelial differentiation of mesenchymal stem cells and repairs bleomycin-induced lung injury. *Am J Physiol Cell Physiol* 2014; **307**: C234-C244 [PMID: 24898581 DOI: 10.1152/ajpcell.00366.2013]
- 24 **Dijksterhuis JP,** Petersen J, Schulte G. WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3. *Br J Pharmacol* 2014; **171**: 1195-1209 [PMID: 24032637 DOI: 10.1111/bph.12364]
- 25 **Kim JT,** Liu C, Zaytseva YY, Weiss HL, Townsend CM Jr, Evers BM. Neurotensin, a novel target of Wnt/ $\beta$ -catenin pathway, promotes growth of neuroendocrine tumor cells. *Int J Cancer* 2015; **136**: 1475-1481 [PMID: 25098665 DOI: 10.1002/ijc.29123]
- 26 **Gibbons GS,** Owens SR, Fearon ER, Nikolovska-Coleska Z. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L. *ACS Chem Biol* 2015; **10**: 109-114 [PMID: 25361163 DOI: 10.1021/cb500668u]

**P- Reviewer:** Facciorusso A, Musquer N, Shin T **S- Editor:** Gong ZM  
**L- Editor:** Filipodia **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>



ISSN 1007-9327

